RHHBYLicensingprnewswire

Foresight Diagnostics and Roche Enter Licensing Agreement for PhasED-Seq™ Technology in Non-Hodgkin's Lymphoma

Sentiment:Neutral (60)

Summary

(RHHBY) The Agreement Closes the Litigation Between the Parties BOULDER, Colo., Aug. 29, 2025 /PRNewswire/ -- Foresight Diagnostics ("Foresight") today announced that it has entered into a limited licensing agreement with Roche Molecular Systems and Roche Sequencing Systems (together, "Roche")...

Original Article

Read the full article from the original source for complete details and context.

Read Full Article

Article published on August 30, 2025 by prnewswire